Fu Wei is Founder and CEO of CBC Group, Asia’s largest healthcare-dedicated asset management firm, headquartered in Singapore. He oversees the firm’s overall strategy, talent development, and is responsible for maintaining the firm’s long-term partnerships with global investors. As a seasoned investor, Fu Wei was instrumental in incubating several biotech and pharmaceutical companies, including I-MAB (Nasdaq: IMAB), Everest Medicines (1952.HK), Jadeite Medicines (Japan), RVAC Medicines (Singapore), A-BioX (U.S.) and Ensem Therapeutics (U.S.). He is the Chairman of the Board at Everest Medicines and an Independent Director of I-MAB. Prior to founding CBC Group in 2014, he was formerly the General Manager of the investment department at a wholly owned subsidiary of Far East Horizon Limited (HKEX:3360). He has also worked for Standard Chartered Bank (China), Macquarie Capital (Singapore) and Temasek Holdings. Mr. Fu was named among China’s Top 30 Investors in 2021 by Forbes China. Under his leadership, CBC Group was recognized by PEI in 2022 as the #1 private equity firm in Singapore, with the Group’s AUM having grown from US$180 million in 2014 to over US$7 billion today.
